Adjuvant nab-paclitaxel plus S-1 versus oxaliplatin plus capecitabine after curative D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase 3 open-label, randomized controlled trial

被引：0
|
作者：
Yu Pengfei
Du, Yian
Xu, Zhiyuan
Yang, Litao
Ying, Jieer
Chen, Ping
Wei, Yunhai
Wu, Yingjie
Yan, Zhilong
Xu, Hongtao
Zhang, Xiaojing
Li, Yong
Zheng, Zhichao
Chen, Zhiheng
Cheng, Xiangdong
机构：
[1] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Ningbo Second Hosp, Ningbo, Peoples R China
[3] Zhejiang Univ, Huzhou Hosp, Huzhou Cent Hosp, Huzhou, Peoples R China
[4] Ningbo Univ, Affiliated Peoples Hosp, Ningbo, Peoples R China
[5] Ningbo First Hosp, Ningbo, Peoples R China
[6] Lishui Cent Hosp, Lishui, Peoples R China
[7] Huzhou Teachers Coll, Affiliated Hosp, 1 Peoples Hosp Huzhou, Huzhou, Peoples R China
[8] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
[9] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[10] First Hosp Jiaxing, Jiaxing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
386
引用
收藏
页码：386 / 386
页数：1
相关论文
共 50 条
  • [41] Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy
    Kazumasa Fujitani
    Shigeyuki Tamura
    Yutaka Kimura
    Takeshi Tsuji
    Jin Matsuyama
    Shohei Iijima
    Hiroshi Imamura
    Kentaro Inoue
    Kenji Kobayashi
    Yukinori Kurokawa
    Toshio Shimokawa
    Toshimasa Tsujinaka
    Hiroshi Furukawa
    Gastric Cancer, 2014, 17 : 348 - 353
  • [42] FIVE-YEAR OUTCOMES OF A PHASE II STUDY OF ADJUVANT CHEMOTHERAPY WITH S-1 PLUS DOCETAXEL FOR STAGE III GASTRIC CANCER AFTER CURATIVE D2 GASTRECTOMY
    Shigeyuki, Tamura
    Kazumasa, Fujitani
    Yutaka, Kimura
    Takeshi, Tsuji
    Shohei, Iijima
    Jin, Matsuyama
    Hiroshi, Imamura
    Kentarou, Inoue
    Kenji, Kobayashi
    Yukinori, Kurokawa
    Toshio, Shimokawa
    Toshimasa, Tsujinaka
    Hiroshi, Furukawa
    ANNALS OF ONCOLOGY, 2014, 25 : 40 - 40
  • [43] Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy
    Fujitani, Kazumasa
    Tamura, Shigeyuki
    Kimura, Yutaka
    Tsuji, Takeshi
    Matsuyama, Jin
    Iijima, Shohei
    Imamura, Hiroshi
    Inoue, Kentaro
    Kobayashi, Kenji
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    GASTRIC CANCER, 2014, 17 (02) : 348 - 353
  • [44] Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial
    Zhichao Jiang
    Yibin Xie
    Wen Zhang
    Chunxia Du
    Yuxin Zhong
    Yuelu Zhu
    Liming Jiang
    Lizhou Dou
    Kang Shao
    Yongkun Sun
    Qi Xue
    Yantao Tian
    Shugeng Gao
    Dongbing Zhao
    Aiping Zhou
    Gastric Cancer, 2024, 27 : 571 - 579
  • [45] Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial
    Jiang, Zhichao
    Xie, Yibin
    Zhang, Wen
    Du, Chunxia
    Zhong, Yuxin
    Zhu, Yuelu
    Jiang, Liming
    Dou, Lizhou
    Shao, Kang
    Sun, Yongkun
    Xue, Qi
    Tian, Yantao
    Gao, Shugeng
    Zhao, Dongbing
    Zhou, Aiping
    GASTRIC CANCER, 2024, 27 (03) : 571 - 579
  • [46] Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study
    Jiang, Zhichao
    Sun, Yongkun
    Zhang, Wen
    Cui, Chengxu
    Yang, Lin
    Zhou, Aiping
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (03) : 180 - 186
  • [47] Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial (vol 22, pg 1081, 2021)
    Zhang, Xiaotian
    Liang, Han
    Li, Ziyu
    Xue, Yingwei
    Wang, Yanong
    Zhou, Zhiwei
    Yu, Jiren
    Bu, Zhaode
    Chen, Lin
    Du, Yian
    Wang, Xinbao
    Wu, Aiwen
    Li, Guoli
    Su, Xiangqian
    Xiao, Gang
    Cui, Ming
    Wu, Dan
    Chen, Li
    Wu, Xiaojiang
    Zhou, Yanbing
    Zhang, Lianhai
    Dang, Chengxue
    He, Yulong
    Zhang, Zhongtao
    Sun, Yihong
    Li, Yong
    Chen, Huanqiu
    Bai, Yuxian
    Qi, Changsong
    Yu, Peiwu
    Zhu, Guanbao
    Suo, Jian
    Jia, Baoqing
    Li, Leping
    Huang, Changming
    Li, Fei
    Ye, Yingjiang
    Xu, Huimian
    Wang, Xin
    Yuan, Yannan
    Jian-Yu, E.
    Ying, Xiangji
    Yao, Chen
    Shen, Lin
    Ji, Jiafu
    LANCET ONCOLOGY, 2021, 22 (08): : E347 - E347
  • [48] S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial
    Kang, Yoon-Koo
    Chin, Keisho
    Chung, Hyun Cheol
    Kadowaki, Shigenori
    Oh, Sang Cheul
    Nakayama, Norisuke
    Lee, Keun-Wook
    Hara, Hiroki
    Chung, Ik-Joo
    Tsuda, Masahiro
    Park, Se Hoon
    Hosaka, Hisashi
    Hironaka, Shuichi
    Miyata, Yoshinori
    Ryu, Min-Hee
    Baba, Hideo
    Hyodo, Ichinosuke
    Bang, Yung-Jue
    Boku, Narikazu
    LANCET ONCOLOGY, 2020, 21 (08): : 1045 - 1056
  • [49] NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma
    Dean, Andrew
    Wainberg, Zev A.
    Bekaii-Saab, Tanios S.
    Hubner, Richard
    Macarulla, Teresa
    Paulson, Andrew Scott
    Cutsem, Eric V.
    Maxwell, Fiona
    Moore, Yan
    Wang, Haofei Tiffany
    Zhang, Bin
    O'Reilly, Eileen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 202 - 203
  • [50] Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: A randomized phase III trial (RESOLVE trial)
    Ji, J.
    Shen, L.
    Li, Z.
    Zhang, X.
    Liang, H.
    Xue, Y.
    Wang, Y.
    Zhou, Z.
    Yu, J.
    Chen, L.
    Du, Y.
    Li, G.
    Xiao, G.
    Wu, D.
    Zhou, Y.
    Dang, C.
    He, Y.
    Zhang, Z.
    Sun, Y.
    Li, Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 877 - 877
12345